147 related articles for article (PubMed ID: 38634916)
41. Notch2 Increases the Resistance to Venetoclax-Induced Apoptosis in Chronic Lymphocytic Leukemia B Cells by Inducing Mcl-1.
Fiorcari S; Maffei R; Atene CG; Mesini N; Maccaferri M; Leonardi G; Martinelli S; Paolini A; Nasillo V; Debbia G; Potenza L; Luppi M; Marasca R
Front Oncol; 2021; 11():777587. PubMed ID: 35070982
[TBL] [Abstract][Full Text] [Related]
42. SARS-CoV-2 Omicron Variant in Patients With Chronic Lymphocytic Leukemia: Case Series.
Khamees I; Ali EA; Malkawi L; Rozi W; Yassin MA
Cureus; 2022 Nov; 14(11):e32041. PubMed ID: 36600852
[TBL] [Abstract][Full Text] [Related]
43. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.
Soumerai JD; Mato AR; Dogan A; Seshan VE; Joffe E; Flaherty K; Carter J; Hochberg E; Barnes JA; Hamilton AM; Abramson JS; Batlevi CL; Matasar MJ; Noy A; Owens CN; Palomba ML; Kumar A; Takvorian T; Ni A; Choma M; Friedman C; Chadha P; Simkins E; Ruiters J; Sechio S; Portman D; Ramos L; Nolet N; Mahajan N; Martignetti R; Mi J; Scorsune K; Lynch J; McGree B; Hughes S; Grieve C; Roeker LE; Thompson M; Johnson PC; Roshal M; Huang J; Biondo J; Wu Q; Jacob A; Abdel-Wahab O; Zelenetz AD
Lancet Haematol; 2021 Dec; 8(12):e879-e890. PubMed ID: 34826411
[TBL] [Abstract][Full Text] [Related]
44. Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia.
Muhowski EM; Ravikrishnan J; Gordon B; Yu L; Misra S; Walker B; Eathiraj S; Sampath D; Rogers KA; Byrd JC; Woyach JA
J Hematol Oncol; 2022 Nov; 15(1):166. PubMed ID: 36380319
[TBL] [Abstract][Full Text] [Related]
45. Venetoclax ramp-up with concurrent voriconazole in a patient with chronic lymphocytic leukemia.
Krapfl A; McLeod C; Myers R; Venugopal P; Seddon A
J Oncol Pharm Pract; 2022 Dec; 28(8):1898-1901. PubMed ID: 35179064
[TBL] [Abstract][Full Text] [Related]
46. Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study.
Autore F; Innocenti I; Reda G; Visentin A; Vitale C; Piciocchi A; Fresa A; Leone MMA; Farina L; Quaresmini G; Baratè C; Giordano A; Ferrari A; Angeletti I; De Paolis MR; Malerba L; Chiurazzi F; Loseto G; Catania G; Sportoletti P; Scortechini I; Moia R; Gentile M; Rigolin GM; Mattiello V; Gattei V; Coscia M; Trentin L; Foà R; Cuneo A; Laurenti L
Hematol Oncol; 2023 Dec; 41(5):877-883. PubMed ID: 37392141
[TBL] [Abstract][Full Text] [Related]
47. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
48. Venetoclax in the Treatment of Chronic Lymphocytic Leukemia: Evidence, Expectations, and Future Prospects.
Tariq S; Tariq S; Khan M; Azhar A; Baig M
Cureus; 2020 Jun; 12(6):e8908. PubMed ID: 32742874
[TBL] [Abstract][Full Text] [Related]
49. Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma.
Lu X; Emond B; Qureshi ZP; Wu LH; Forbes SP; Hilts A; Liu S; Lafeuille MH; Lefebvre P; Huang Q; Rogers KA
Curr Med Res Opin; 2023 Sep; 39(9):1227-1235. PubMed ID: 37530387
[TBL] [Abstract][Full Text] [Related]
50. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
Siddiqi T; Maloney DG; Kenderian SS; Brander DM; Dorritie K; Soumerai J; Riedell PA; Shah NN; Nath R; Fakhri B; Stephens DM; Ma S; Feldman T; Solomon SR; Schuster SJ; Perna SK; Tuazon SA; Ou SS; Papp E; Peiser L; Chen Y; Wierda WG
Lancet; 2023 Aug; 402(10402):641-654. PubMed ID: 37295445
[TBL] [Abstract][Full Text] [Related]
51. Risks and outcomes of hospitalizations in patients with chronic lymphocytic leukemia admitted with immune thrombocytopenia: an analysis of the National Inpatient Sample Database.
Ammad Ud Din M; Mahmud A; Mostafa M; Shahzad M; Liaqat H; Pinilla-Ibarz J; Jaglal M
Ann Hematol; 2023 Apr; 102(4):889-895. PubMed ID: 36781419
[TBL] [Abstract][Full Text] [Related]
52. Emergence of Chronic Lymphocytic Leukemia During Admission for COVID-19: Cause or Coincidence?
Saluja P; Gautam N; Amisha F; Safar M; Bartter T
Cureus; 2022 Mar; 14(3):e23470. PubMed ID: 35494899
[TBL] [Abstract][Full Text] [Related]
53. SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort.
Merli M; Ferrarini I; Merli F; Busca A; Mina R; Falini B; Bruna R; Cairoli R; Marchetti M; Romano A; Cavo M; Arcaini L; Trentin L; Cattaneo C; Derenzini E; Fracchiolla NS; Marchesi F; Scattolin A; Billio A; Bocchia M; Massaia M; Gambacorti-Passerini C; Mauro FR; Gentile M; Mohamed S; Della Porta MG; Coviello E; Cilloni D; Visani G; Federici AB; Tisi MC; Cudillo L; Galimberti S; Gherlinzoni F; Pagano L; Guidetti A; Bertù L; Corradini P; Passamonti F; Visco C
Hematol Oncol; 2023 Feb; 41(1):128-138. PubMed ID: 36265128
[TBL] [Abstract][Full Text] [Related]
54. Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.
Roberts AW; Stilgenbauer S; Seymour JF; Huang DCS
Clin Cancer Res; 2017 Aug; 23(16):4527-4533. PubMed ID: 28100580
[TBL] [Abstract][Full Text] [Related]
55. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
[TBL] [Abstract][Full Text] [Related]
56. Venetoclax for the treatment of chronic lymphocytic leukemia.
Gentile M; Petrungaro A; Uccello G; Vigna E; Recchia AG; Caruso N; Bossio S; De Stefano L; Palummo A; Storino F; Martino M; Morabito F
Expert Opin Investig Drugs; 2017 Nov; 26(11):1307-1316. PubMed ID: 28972395
[TBL] [Abstract][Full Text] [Related]
57. Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia.
Samuels C; Abbott D; Niemiec S; Tobin J; Falco A; Halsema K; Kamdar M
Cancer Rep (Hoboken); 2022 May; 5(5):e1505. PubMed ID: 34250757
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax.
Avsec D; Škrlj Miklavčič M; Burnik T; Kandušer M; Bizjak M; Podgornik H; Mlinarič-Raščan I
Cell Death Dis; 2022 Oct; 13(10):860. PubMed ID: 36209148
[TBL] [Abstract][Full Text] [Related]
59. Successful treatment of relapsed chronic lymphocytic leukemia with venetoclax in a patient with severe chronic kidney disease.
Sugiura H; Sezaki N; Ishikawa T; Kuroi T; Okamoto S; Nomura N; Masunari T; Nakasako Y; Kiguchi T; Tanimoto M
Clin Case Rep; 2022 Apr; 10(4):e05735. PubMed ID: 35441018
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
